KLF9 and endometrial cancer: 200b up-regulates MMP2 activity by targeting TIMP2, 200c targets ZEB1/2, VEGFA, FLT1, IKKβ, KLF9, FBLN5, and TIMP 2, 200c epxression changes upon transition into cancerous cells; reintroduction of miR-200c lowers aggressiveness (migration and invasion) of endometrial cancer cells; miR-200b/c and 429 induce cisplatin resistance by inhibiting AP-2α expression